Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
J&J Submits For EMA Approval For DARZALEX SC Quadruplet Regimen In Newly Diagnosed Multiple Myeloma
Janssen-Cilag International NV submitted a Type II variation application to the EMA for DARZALEX SC formulation in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for newly diagnosed multiple myeloma (NDMM), supported by the Phase 3 CEPHEUS study showing 60.9% MRD-negativity and a 43% reduction in progression or death risk.
New life-changing myeloma drug approved for fourth-line use on the NHS for those
Teclistamab (Tecvayli), a Johnson & Johnson drug, is now recommended by NICE for fourth-line use on the NHS in England and Wales for myeloma patients who have exhausted other treatments. This decision follows similar approval in Scotland and aims to provide relief to those with triple-class refractory myeloma.
Johnson & Johnson discontinues Phase III study of treatment for bladder cancer
The article discusses the importance of SSR (Server-Side Rendering) in web development, highlighting its role in improving performance and user experience. It mentions the use of specific JavaScript files for SSR implementation and the hidden nature of certain elements for optimized rendering.
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX
Janssen-Cilag International NV submits Type II variation application to EMA for DARZALEX® (daratumumab) SC formulation in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for newly diagnosed multiple myeloma (NDMM) patients not planning initial transplant. Data from Phase 3 CEPHEUS study shows D-VRd significantly improves MRD-negativity and reduces progression or death risk compared to standard VRd regimen.
Related Clinical Trials:
GSK strikes £1.7bn deal over Zantac cancer claims
GSK will pay up to £1.7billion to settle claims that its heartburn drug Zantac caused cancer, ending a five-year legal saga.
World Companion Diagnostics and Liquid Biopsy Summit APAC to Unite 100+ Precision
The World Companion Diagnostics & Liquid Biopsy Summit APAC, Nov 13-14, 2024 in Singapore, brings together experts to discuss NGS, biomarker development, and clinical trial assay advancements. The event offers networking, insights, and discussions on regulatory guidelines, market access, and novel technologies for precision medicine.
Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application
David Baker, Demis Hassabis, and John Jumper won the 2023 Nobel Prize in chemistry for computational protein design and AlphaFold development. Alnylam Pharmaceuticals seeks FDA approval for vutrisiran in another form of transthyretin amyloidosis. Johnson & Johnson terminated TAR-200 trial in bladder cancer. Gemma Biotherapeutics partners with Brazil's Fiocruz for rare disease gene therapies. AstraZeneca acquires a preclinical cholesterol-lowering drug from CPSC Pharmaceutical Group. Astellas invests in AviadoBio's experimental gene therapy for frontotemporal dementia.
Johnson & Johnson completes V-Wave acquisition
V-Wave's Ventura Interatrial Shunt System, designed for heart failure with reduced ejection fraction (HFrEF), received FDA's breakthrough device designation in 2019. The device, implanted via an interventional procedure, showed significant relief for HFrEF patients in the RELIEVE-HF trial, but not for those with preserved ejection fraction.
Related Clinical Trials:
This week in R&D: ULA launches second rocket, Microsoft sets up AI in Italy, and India and ...
R&D World Index (RDWI) closed at 4,005.40, up 0.62%. Eight members gained, led by Alibaba (+6.71%), while 17 lost value, with Stellantis NV (-17.06%). Highlights include ULA's second Vulcan Centaur rocket launch, Microsoft's $4.75B investment in Italy's cloud and AI, Eli Lilly's $4.5B drug center, and India-US R&D collaboration talks.
Global Dermatology Drugs Market to Worth Over US$ 50.42
The global dermatology drugs market is projected to reach $50.42 billion by 2032 from $19.71 billion in 2023, driven by innovations in AI, genomics, and personalized medicine. Key players like Novartis, Pfizer, and Johnson & Johnson lead with advanced treatments, while Europe's high prevalence of skin conditions and robust healthcare infrastructure support market growth.
© Copyright 2025. All Rights Reserved by MedPath